Several studies have reported that equol can decrease serum PSA levels by its antiandrogenic action on 5-alpha-dehydro testosterone, decrease prostate size, and thus reduce the risk of prostate cancer [15, 16, 43, 44]. The gene discussed is KLK3; the disease is prostate carcinoma.